Tonix reports preclinical data for TNX-1700 and TNX-4700 at AACR 2026

Tonix Pharmaceuticals Holding Corp.

TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mouse model.
TNX-1700 showed dose-independent linear PK in non-human primates and transgenic mice; no significant weight loss.
TNX-4700 anti-BTLA mAbs demonstrated potent, high-affinity binding and functional antagonism in vitro.
Three TNX-4700 antagonists had reduced FcgRI binding and no FcgRIIB binding, potentially lowering FcR-dependent toxicities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.